Peptide Bioavailability
Improve Peptide Bioavailability Without Sacrificing Activity
Poor bioavailability is the leading cause of peptide drug failure. PeptiGen AI combines computational modeling with translational chemistry to identify structural modifications that enhance absorption and systemic exposure while preserving your peptide's biological activity.
Why Peptide Bioavailability Remains a Critical Bottleneck
Peptides face a fundamental pharmacokinetic challenge: their size, charge, and susceptibility to proteolytic degradation severely limit oral absorption and systemic exposure. Most therapeutic peptides require parenteral administration, restricting patient access and commercial potential.
Traditional medicinal chemistry approaches to improving bioavailability often compromise the structural features responsible for target binding. The challenge is not simply improving absorption — it is doing so while maintaining the precise three-dimensional geometry that drives potency and selectivity.
PeptiGen AI addresses this challenge through a multi-parameter optimization framework that simultaneously evaluates absorption, metabolic stability, membrane permeability, and biological activity — identifying modifications that improve the pharmacokinetic profile without eroding the pharmacodynamic signature.
Our Bioavailability Enhancement Approach
Permeability Prediction Modeling
Computational assessment of passive transcellular permeability, efflux transporter liability, and paracellular transport potential using validated in silico models calibrated against experimental Caco-2 and PAMPA data.
Proteolytic Stability Engineering
Identification of protease-susceptible cleavage sites followed by targeted backbone modifications — N-methylation, D-amino acid substitution, cyclization — to extend plasma and gastrointestinal half-life.
Lipophilicity Optimization
Systematic evaluation of lipophilicity-permeability relationships to identify the optimal logP/logD window for your target tissue, balancing membrane partitioning against aqueous solubility requirements.
Prodrug Strategy Assessment
Evaluation of reversible prodrug approaches — ester, carbamate, and phosphate masking of polar groups — to improve oral absorption while enabling in vivo regeneration of the active peptide.
Bioavailability Optimization Workflow
Baseline Pharmacokinetic Profiling
Computational prediction of key PK parameters: permeability, plasma protein binding, metabolic stability, and efflux transporter substrate potential for your lead peptide.
Liability Identification
Systematic identification of structural features limiting bioavailability: protease cleavage sites, hydrogen bond donors, polar surface area, and molecular flexibility.
Modification Strategy Design
Generation of targeted structural modifications addressing identified liabilities, with computational prediction of impact on both PK properties and biological activity.
Multi-Parameter Optimization
Pareto analysis of the bioavailability-activity trade-off space to identify candidates with the optimal balance of pharmacokinetic improvement and pharmacodynamic retention.
Candidate Prioritization
Scientist-reviewed shortlist of 3–8 candidates ranked by predicted bioavailability improvement, synthesis feasibility, and activity retention confidence.
Parameters Evaluated
What You Receive
Bioavailability Assessment Report
Comprehensive computational analysis of your lead peptide's pharmacokinetic liabilities with quantitative predictions for key ADME parameters.
Modification Strategy Document
Prioritized list of structural modifications with predicted impact on permeability, stability, and activity, including synthesis feasibility assessment.
Optimized Candidate Sequences
3–8 modified peptide sequences with predicted PK profiles, activity retention scores, and recommended experimental validation assays.
Experimental Validation Plan
Prioritized assay recommendations (Caco-2, PAMPA, plasma stability, in vivo PK) to confirm computational predictions with minimal resource expenditure.
All predictions are computational estimates. Experimental validation is required before clinical development decisions.
Who This Service Is For
Academic Drug Discovery Groups
Research teams with potent peptide hits that require pharmacokinetic optimization before industry partnership or licensing discussions.
Biotech Companies
Organizations with peptide leads in early development seeking to improve oral bioavailability or reduce dosing frequency for competitive differentiation.
Technology Transfer Offices
TTOs evaluating peptide assets for licensing potential, where bioavailability data significantly impacts commercial valuation and partner interest.
Frequently Asked Questions
Ready to Improve Your Peptide's Pharmacokinetic Profile?
Submit your peptide sequence for a confidential bioavailability assessment. Our team will evaluate your compound's pharmacokinetic liabilities and identify the most promising optimization strategies.
All submissions are treated as confidential. We recommend filing provisional patent protection before sharing unpublished sequences.